Citadel Advisors
DNTH icon

Citadel Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Citadel Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$562K Buy
+6,700
New +$388K ﹤0.01% 9020
2025
Q4 		– Sell
-29,700
Closed -$1.17M – 12910
2025
Q3 		$1.17M Buy
+29,700
New +$759K ﹤0.01% 7195
2025
Q2 		– Sell
-100
Closed -$1.81K – 13053
2025
Q1 		$1.81K Sell
100
-300
-75% -$6.61K ﹤0.01% 14095
2024
Q4 		$8.72K Hold
400
– – ﹤0.01% 13675
2024
Q3 		$11K Buy
+400
New +$11.1K ﹤0.01% 13177
2023
Q4 		– Sell
-276
Closed -$3.77K – 14446
2023
Q3 		$3.77K Sell
276
-605
-69% -$7.62K ﹤0.01% 13550
2023
Q2 		$10.7K Sell
881
-50
-5% -$569 ﹤0.01% 13186
2023
Q1 		$11.8K Sell
931
-682
-42% -$7.55K ﹤0.01% 13453
2022
Q4 		$10.2K Buy
+1,613
New +$28.6K ﹤0.01% 13640
2021
Q4 		– Sell
-738
Closed -$86K – 13957
2021
Q3 		$86K Buy
+738
New +$86K ﹤0.01% 13007

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's DNTH Position: Q1 2026 in Review

Citadel Advisors increased its Dianthus Therapeutics (DNTH) stake by 51% in Q1 2026, buying an estimated $31.4M and bringing the position to 1,610,483 shares worth $135M. The position accounts for 0.02% of the portfolio, ranked #636.

Citadel Advisors first reported a position in DNTH in Q2 2018 and has held it in 26 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Citadel Advisors held 1,610,483 shares of Dianthus Therapeutics worth $135M as of Q1 2026.
  • Citadel Advisors bought 541,549 Dianthus Therapeutics shares in Q1 2026, an estimated $31.4M.
  • Dianthus Therapeutics made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #636 holding.
  • Citadel Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 26 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.